Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort

Raphael Carapito,Richard Li,Julie Helms,Christine Carapito,Sharvari Gujja,Véronique Rolli,Raony Guimaraes,Jose Malagon-Lopez,Perrine Spinnhirny,Alexandre Lederle,Razieh Mohseninia,Aurélie Hirschler,Leslie Muller,Paul Bastard,Adrian Gervais,Qian Zhang,François Danion,Yvon Ruch,Maleka Schenck,Olivier Collange,Thiên-Nga Chamaraux-Tran,Anne Molitor,Angélique Pichot,Alice Bernard,Ouria Tahar,Sabrina Bibi-Triki,Haiguo Wu,Nicodème Paul,Sylvain Mayeur,Annabel Larnicol,Géraldine Laumond,Julia Frappier,Sylvie Schmidt,Antoine Hanauer,Cécile Macquin,Tristan Stemmelen,Michael Simons,Xavier Mariette,Olivier Hermine,Samira Fafi-Kremer,Bernard Goichot,Bernard Drenou,Khaldoun Kuteifan,Julien Pottecher,Paul-Michel Mertes,Shweta Kailasan,M Javad Aman,Elisa Pin,Peter Nilsson,Anne Thomas,Alain Viari,Damien Sanlaville,Francis Schneider,Jean Sibilia,Pierre-Louis Tharaux,Jean-Laurent Casanova,Yves Hansmann,Daniel Lidar,Mirjana Radosavljevic,Jeffrey R Gulcher,Ferhat Meziani,Christiane Moog,Thomas W Chittenden,Seiamak Bahram,M. Javad Aman,Jeffrey R. Gulcher,Thomas W. Chittenden

DOI: https://doi.org/10.1126/scitranslmed.abj7521

IF: 17.1

2022-01-19

Science Translational Medicine

Abstract:The drivers of critical coronavirus disease 2019 (COVID-19) remain unknown. Given major confounding factors such as age and comorbidities, true mediators of this condition have remained elusive. We used a multi-omics analysis combined with artificial intelligence in a young patient cohort where major comorbidities were excluded at the onset. The cohort included 47 “critical” (in the intensive care unit under mechanical ventilation) and 25 “non-critical” (in a non-critical care ward) patients with COVID-19 and 22 healthy individuals. The analyses included whole-genome sequencing, whole-blood RNA sequencing, plasma and blood mononuclear cell proteomics, cytokine profiling, and high-throughput immunophenotyping. An ensemble of machine learning, deep learning, quantum annealing, and structural causal modeling were used. Patients with critical COVID-19 were characterized by exacerbated inflammation, perturbed lymphoid and myeloid compartments, increased coagulation, and viral cell biology. Among differentially expressed genes, we observed up-regulation of the metalloprotease ADAM9 . This gene signature was validated in a second independent cohort of 81 critical and 73 recovered patients with COVID-19 and was further confirmed at the transcriptional and protein level and by proteolytic activity. Ex vivo ADAM9 inhibition decreased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uptake and replication in human lung epithelial cells. In conclusion, within a young, otherwise healthy, cohort of individuals with COVID-19, we provide the landscape of biological perturbations in vivo where a unique gene signature differentiated critical from non-critical patients. We further identified ADAM9 as a driver of disease severity and a candidate therapeutic target.

cell biology,medicine, research & experimental